prr is destined to achieve greatness, page-30

"I certainly believe our work will pay off for both the
patients and our shareholders in due course."

That above coming from Mr Conservative (Mathew Lehman) means much. But, of course, he is not providing any guarantees - no one can. However, I cannot help but feel quietly confident that we (holders) are on a winner.

The current share price and predicted share price of 6 cents in a couple of months is meaningless. It is where the price is at, come November that is important. If the trial results disappoint, well bye bye investment. On the other hand, if the trial results are good - who knows where the share price will be.

I am of the opinion, that the FDA believe that there is a very good chance that the phase 2b results are likely to be positive, otherwise why would they give the go ahead to proceed with the phase 3 trials. Just think about it, would the FDA agree to putting approx 1000 cancer sufferers through phase 3 trials if they thought that the whole thing would fall over on completion of phase 2b! I do not think that they would. If there was, even a 50-50 chance of that happening, I believe that the FDA would say "Dr Frazer, we want to see the phase 2b results before we give you the go ahead to proceed with phase 3 trials".

All is good - in my opinion.